Loading...

PE anti-mouse CD4 Antibody

Pricing & Availability
Clone
RM4-5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
1_RM4-5_PE_030206
C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 1_RM4-5_PE_030206
    C57BL/6 mouse splenocytes stained with CD4 (clone RM4-5) PE (filled histogram) or rat IgG2a, κ PE isotype control (open histogram).
  • 2_RM4-5_PE_CD4_Antibody_2_040122
    C57BL/6 mouse splenocytes were stained with CD4 (clone RM4-5) PE (solid line) or rat IgG2b, κ PE isotype control (dashed line).
See PE spectral data
Cat # Size Price Quantity Check Availability Save
100511 50 µg 20€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100512 200 µg 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes and a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a co-receptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
BALB/c mouse thymocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4+ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4+ cells1, and immunohistochemistry of acetone-fixed frozen tissue sections2,3,11 and paraffin-embedded sections11. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

(PubMed link indicates BioLegend citation)
  1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
  2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
  3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
  4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
  5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
  6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
  7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
  8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
  9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
  10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
  11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)
Product Citations
  1. Bradley CP et al. 2017. Cell host & microbe. 22(5):697-704 . PubMed
  2. Ibrahim ML, et al. 2018. Cell Rep. 25:3036. PubMed
  3. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  4. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  5. Omenetti S, et al. 2019. Immunity. 51:77. PubMed
  6. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  7. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  8. Jayachandran R, et al. 2019. Immunity. 50:152. PubMed
  9. Yuan X, et al. 2017. Elife. 6:e29540. PubMed
  10. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  11. Ma C, et al. 2018. Science. 360:eaan5931. PubMed
  12. Zhi Y, et al. 2020. Int J Mol Med. 45:1327. PubMed
  13. Thomas AM, et al. 2020. Journal of Cellular Physiology. 235(6):5120-5129.. PubMed
  14. Karagiannis F, et al. 2020. Immunity. 52(4):620-634. PubMed
  15. Steinmann S, et al. 2020. Sci Rep. 1.160416667. PubMed
  16. Fulham MA, et al. 2019. Am J Physiol Cell Physiol. 317:C687. PubMed
  17. Diamond M, et al. 2011. J Exp Med. 208:1989. PubMed
  18. Mohan J, et al. 2013. J Exp Med. 210:2403. PubMed
  19. Huang J, et al. 2014. J Immunol. 192:1972. PubMed
  20. Schadler K, et al. 2014. Cancer Res. 74:2171. PubMed
  21. Nakajima A, et al. 2014. PLoS One. 9:105904. PubMed
  22. Onishi M, et al. 2015. J Immunol. 194:2673. PubMed
  23. Sharma S, et al. 2015. J Immunol. 194:5529. PubMed
  24. Suzuki M, et al. 2015. J Immunol. 195: 1273-1281. PubMed
  25. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  26. Toomer K, et al. 2016. J Immunol. 196: 3665 - 3676. PubMed
  27. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  28. Miura N, et al. 2017. Mol Ther. 10.1016/j.ymthe.2017.01.020. PubMed
  29. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  30. Haniuda K, et al. 2020. Cell Rep. 33:108333. PubMed
  31. Alshetaiwi H, et al. 2020. Sci Immunol. 5:00. PubMed
  32. Galeano Niño JL, et al. 2020. J Cell Sci. 133:00:00. PubMed
  33. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  34. Prizant H, et al. 2021. Cell Reports. 36:109523. PubMed
  35. Prasad M, et al. 2020. Cell Mol Immunol. . PubMed
  36. Ruer-Laventie J, et al. 2020. Bio Protoc. e3531:10. PubMed
  37. Mohammadi MR, et al. 2021. Commun Biol. 4:685. PubMed
  38. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  39. Roy S, et al. 2021. Nat Commun. 12:3182. PubMed
  40. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  41. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  42. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  43. Li H, et al. 2020. Nature. 584:274. PubMed
  44. Mendelsohn AC, et al. 2020. Am J Physiol Cell Physiol. 319:C997. PubMed
  45. Rashid MH, et al. 2021. Oncol Rep. 45:1171. PubMed
  46. Suzuki M, et al. 2021. Sci Adv. 7:. PubMed
  47. Galeano Niño JL, et al. 2020. J Cell Sci. . PubMed
  48. Chen LH, et al. 2021. Sci Rep. 11:19478. PubMed
  49. Yang R, et al. 2022. J Adv Res. 35:259. PubMed
  50. Tang S, et al. 2022. Virol J. 19:32. PubMed
  51. Achmus L, et al. 2020. Front Neurol. 11:577971. PubMed
  52. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
  53. Ali S, et al. 2021. PLoS One. 16:e0246646. PubMed
  54. Liang K, et al. 2021. Clin Transl Immunology. 10:e1293. PubMed
  55. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
  56. Qin Y, et al. 2021. Cell Rep. 37:109968. PubMed
  57. Li J, et al. 2021. Cell Rep. 37:110124. PubMed
  58. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  59. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  60. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  61. Sugiura A, et al. 2022. Immunity. 55:65. PubMed
  62. Kumar Das D, et al. 2022. J Biol Chem. 298:102596. PubMed
  63. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  64. Marritt KL, et al. 2023. Front Immunol. 13:1087991. PubMed
  65. Tunali G, et al. 2023. J Clin Invest. :. PubMed
  66. Li L, et al. 2023. iScience. 26:106095. PubMed
  67. Seclì L, et al. 2023. J Immunother Cancer. 11:. PubMed
RRID
AB_312714 (BioLegend Cat. No. 100511)
AB_312715 (BioLegend Cat. No. 100512)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 3    Revision Date: 01/29/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account